Reaching New Frontiers With Founding CEO & Current Director of Generate Biomedicines

TD Cowen Insights

Recorded on 09/28/23

TD Cowen analyst Yaron Werber speaks with Geoff von Maltzahn, general partner at Flagship Pioneering and founding CEO & current Director of Generate Biomedicines, about the AI revolution in biotech, and how generative biology has impacted both the drug development process and his approach towards designing and building companies. The ability of machines to recognize patterns at scale impossible for the human mind could help elucidate the common “rule book” underlying protein interactions, enabling the rapid generation of optimized protein therapies for any given target. More so, unlike human innovation (which tends to dissipate in larger organizations), AI models get wiser the more data flows into them, tapping into an “intelligence of scale” in which greater scale compounds discovery prowess. The key is building the right culture centered around machine learning, enabling data sciences to be the driver and not just aggregator of data, and having the right expertise at both data informatics, science, manufacturing, and technology to achieve scale, and validate and enhance the platform.

For Disclosures, click here bit.ly/3cPHkNW

https://go.td.com/PodcastDisclosure